share_log

康希諾生物：內幕消息 2023年度業績快報公告

CANSINOBIO: INSIDE INFORMATION UPDATES ON 2023 PRELIMINARY ANNUAL RESULTS

香港交易所 ·  Feb 23 07:09
Summary by Moomoo AI
康希諾生物於2024年2月23日發布2023年度業績快報，顯示公司營業收入較上年同期下降65.49%，至357.08億元人民幣。公司歸屬於母公司所有者的淨虧損增加59.14%，達到1,447.30億元人民幣。該虧損增加主要由於新冠疫苗市場需求下降，以及對新冠疫苗產品退回金額的核算與估計。此外，公司營業成本上升，並對存貨和長期資產進行了減值測試，計提了減值損失。儘管流腦疫苗產品銷售收入增長，但新冠疫苗收入的大幅下降導致總收入減少。公司總資產和歸屬於母公司所有者的權益分別下降18.22%和21.31%。康希諾生物提醒投資者，公告中的財務數據為初步核算數據，未經獨立核數師審計或審閱，並將在2023年年報中披露經審計數據。
康希諾生物於2024年2月23日發布2023年度業績快報，顯示公司營業收入較上年同期下降65.49%，至357.08億元人民幣。公司歸屬於母公司所有者的淨虧損增加59.14%，達到1,447.30億元人民幣。該虧損增加主要由於新冠疫苗市場需求下降，以及對新冠疫苗產品退回金額的核算與估計。此外，公司營業成本上升，並對存貨和長期資產進行了減值測試，計提了減值損失。儘管流腦疫苗產品銷售收入增長，但新冠疫苗收入的大幅下降導致總收入減少。公司總資產和歸屬於母公司所有者的權益分別下降18.22%和21.31%。康希諾生物提醒投資者，公告中的財務數據為初步核算數據，未經獨立核數師審計或審閱，並將在2023年年報中披露經審計數據。
CONXINO BIO RELEASED ITS 2023 ANNUAL RESULTS REPORT ON FEBRUARY 23, 2024, SHOWING THAT THE COMPANY'S OPERATING INCOME FELL 65.49% COMPARED TO THE SAME PERIOD LAST YEAR TO RMB357.08 BILLION. The company's net loss attributable to its parent owners increased 59.14% to RMB 1,447.30 billion. The loss was increased primarily due to lower market demand for COVID-19 vaccines and the accounting and estimation of the amount of recoveries for COVID-19 vaccine products. In addition, the company's operating costs rose and depreciation tests were carried out on inventories and long-term assets, accounting for depreciation losses. Despite the increase in revenue from sales of brain vaccine products, a sharp decline in COVID-19 vaccine revenue led to a decrease in overall revenue. The total assets of the company and the interests attributed to the owners of the parent company decreased by 18.22% and 21.31%, respectively. Consino Bios reminds investors that the financial data in the announcement are preliminary audit data, not audited or reviewed by independent auditors and will be disclosed in the 2023 Annual Report.
CONXINO BIO RELEASED ITS 2023 ANNUAL RESULTS REPORT ON FEBRUARY 23, 2024, SHOWING THAT THE COMPANY'S OPERATING INCOME FELL 65.49% COMPARED TO THE SAME PERIOD LAST YEAR TO RMB357.08 BILLION. The company's net loss attributable to its parent owners increased 59.14% to RMB 1,447.30 billion. The loss was increased primarily due to lower market demand for COVID-19 vaccines and the accounting and estimation of the amount of recoveries for COVID-19 vaccine products. In addition, the company's operating costs rose and depreciation tests were carried out on inventories and long-term assets, accounting for depreciation losses. Despite the increase in revenue from sales of brain vaccine products, a sharp decline in COVID-19 vaccine revenue led to a decrease in overall revenue. The total assets of the company and the interests attributed to the owners of the parent company decreased by 18.22% and 21.31%, respectively. Consino Bios reminds investors that the financial data in the announcement are preliminary audit data, not audited or reviewed by independent auditors and will be disclosed in the 2023 Annual Report.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more